Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has metastatic colorectal cancer with primary tumor originating from the rectum~* Has an available archival (recent or remote) tumor, or newly obtained formalin-fixed tissue available for analysis for biomarker studies~* Has at least one measurable lesion greater than or equal to 10 mm~* Disease has progressed after treatment with both irinotecan- and oxaliplatin-containing regimens and should have progressed on or within 3 months of completing their last line of therapy~* Has a performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale~Exclusion Criteria:~* Has poorly-controlled diabetes~* Has received chemotherapy or biological therapy within 2 weeks prior to initial dosing on this study, or whose toxicities from agents administered 2 weeks earlier have not resolved to at least grade 1 or baseline, or who is within 3 weeks from a prior surgery~* Has received radiotherapy within 2 weeks prior to initial dosing on this study, unless the radiotherapy was for management of pain~* Is currently participating or has participated in a study with an investigational compound or device within 30 days or 5 half-lives of the investigational agent, whichever is longer, of initial dosing on this study~* Was unable to complete previous course of irinotecan due to intolerable toxicity, other than discontinuation due to fatigue following prolonged administration (\>4 months exposure)~* Has prior exposure to insulin-like growth factor 1 receptor (IGF-1R) inhibitors or epidermal growth factor receptor (EGFR) inhibitors~* Has a known central nervous system (CNS) metastases and/or carcinomatous meningitis~* Has primary CNS tumor~* Has a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma; potentially curative therapy with no evidence of that disease for 5 years, deemed low risk for recurrence by treating physician.~* Is human immunodeficiency virus (HIV)-positive~* Has active hepatitis B or C infection and is receiving antiviral treatment regimens~* Has symptomatic ascites or pleural effusion~* Is concurrently using growth hormone (GH), or growth hormone inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Dalotuzumab + Irinotecan (Type: EXPERIMENTAL): Participants receive irinotecan intravenously (IV), 180 mg/m\^2 once every two weeks + dalotuzumab IV, 10 mg/kg once weekly, during ≥1 42-day treatment cycle(s).
- Arm B: Cetuximab + Irinotecan (Type: ACTIVE_COMPARATOR): Participants receive cetuximab IV, initial dose of 400 mg/m\^2 and then 250 mg/m\^2 IV weekly + irinotecan IV, 180 mg/m\^2 once every two weeks, during ≥1 42-day treatment cycle(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues